2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

By afschroeder • August 5, 2025

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 2025 Aug 4:ciaf424. doi: 10.1093/cid/ciaf424. Epub ahead of print. PMID: 40757658.

Tags: abatacept, covid-19, Harbor UCLA, Infectious Diseases, infliximab, pemivibart, Publications, vilobelimab

Coronary Artery Calcium in ACC/AHA Prevention Guidelines: Evolution From 2007 to 2026

Irannejad K, Mora R, Krishnan S, Lakshmanan S, Roy S, Budoff MJ. Coronary Artery Calcium in ACC/AHA Prevention Guidelines: Evolution From 2007 to 2026. JACC[...]

Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease

Nalluri K, Goodman EL, Pasupneti T, Nunez G, Wang EC. Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease. JCEM[...]

Effects of normobaric hypoxia and hyperthermia on ventilatory responses to high-intensity interval training bouts

Girardi M, Nicolò A, Marcora SM, Bazzucchi I, Felici F, Dickinson J, Sacchetti M. Effects of normobaric hypoxia and hyperthermia on ventilatory responses to high-intensity[...]